Weekly Top News – Ovarian Cancer – June 29, 2020

June 29, 2020

Aybintio (bevacizumab biosimilar) / Samsung, Mundipharma
Samsung Bioepis Receives Positive CHMP Opinion for AYBINTIO (Bevacizumab) (GlobeNewswire) – Jun 26, 2020 – “Samsung Bioepis Co., Ltd. today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for AYBINTIO®, a biosimilar candidate referencing Avastin®i (bevacizumab). AYBINTIO® has been recommended for approval for the treatment of the same types of cancer as reference bevacizumab in the European Union (EU) including metastatic carcinoma of the colon or rectum (mCRC), metastatic breast cancer (mBC), non-small cell lung cancer (NSCLC), advanced and/or metastatic renal cell cancer (mRCC), epithelial ovarian, fallopian tube and primary peritoneal cancer and cervical cancer.”

No Comments

Post a Comment